نتایج جستجو برای: Pravastatin

تعداد نتایج: 1688  

The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg-1, IP), ADR plus pravastatin (20 mg.kg-1 which was started 5 days prior to ADR injection), and ADR plus pravastatin (20 mg.kg-1 which was started 5 days after ADR injection). On day 20 aft...

The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg-1, IP), ADR plus pravastatin (20 mg.kg-1 which was started 5 days prior to ADR injection), and ADR plus pravastatin (20 mg.kg-1 which was started 5 days after ADR injection). On day 20 aft...

2017
Hiroshi Doi Seiji Matsumoto Soichi Odawara Toshiyuki Shikata Kazuhiro Kitajima Masao Tanooka Yasuhiro Takada Tohru Tsujimura Norihiko Kamikonya Shozo Hirota

Pravastatin is an inhibitor of 3-hydroxy-3-methyl- glutaryl-coenzyme A reductase that has been reported to have therapeutic applications in a range of inflammatory conditions. The aim of the present study was to assess the radioprotective effects of pravastatin in an experimental animal model. Mice were divided into two groups: The control group received ionizing radiation with no prior medicat...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2015
Shinobu Fujii Chikako Setoguchi Kouichi Kawazu Ken-ichi Hosoya

Systemically administered pravastatin effectively treats diabetic retinopathy without central nervous system side effects. The efflux transport mechanism of pravastatin from the brain has already been clarified. In this study, the influx of pravastatin across the blood-retinal and blood-brain barriers (BRB and BBB) and the efflux of pravastatin from the retina were investigated using rats. Prav...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2005
Kari T Kivistö Olaf Grisk Ute Hofmann Konrad Meissner Klaus-Uwe Möritz Christoph Ritter Katja A Arnold Dieter Lutjöohann Klaus von Bergmann Ingrid Klöting Michel Eichelbaum Heyo K Kroemer

The aim of this study was to characterize the role of the efflux transporter Mrp2 (Abcc2) in the pharmacokinetics of orally and intravenously administered pravastatin in rats. Eight Mrp2-deficient TR- rats and eight wild-type rats were given an oral dose of 20 mg/kg pravastatin. Four TR- animals and four wild-type animals were studied after intravenous administration of pravastatin (5 mg/kg). T...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2007
Eiichiro Yamamoto Takuro Yamashita Tomoko Tanaka Keiichiro Kataoka Yoshiko Tokutomi Zhong-Fang Lai Yi-Fei Dong Shinji Matsuba Hisao Ogawa Shokei Kim-Mitsuyama

OBJECTIVE This work was undertaken to investigate comparative effect of AT1 receptor blocker (ARB), 3-hydroxy-3-methylglutaryl (HMG) coenzymeA (CoA) reductase inhibitor (statin), and their combination on vascular injury of salt-sensitive hypertension. METHODS AND RESULTS Salt-loaded Dahl salt-sensitive hypertensive rats (DS rats) were treated with (1) vehicle, (2) hydralazine (5 mg/kg/d), (3)...

Journal: :Drug metabolism and pharmacokinetics 2010
Michiaki Abe Takafumi Toyohara Akiko Ishii Takehiro Suzuki Naoya Noguchi Yasutoshi Akiyama Hiromi O Shiwaku Rie Nakagomi-Hagihara Guodong Zheng Eisuke Shibata Tomokazu Souma Tomohiko Shindo Hirohito Shima Yoichi Takeuchi Eikan Mishima Masayuki Tanemoto Tetsuya Terasaki Tohru Onogawa Michiaki Unno Sadayoshi Ito Shin Takasawa Takaaki Abe

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has been reported to have a beneficial effect on reducing the new onset of diabetes as well as lowering plasma lipids. Because pravastatin is a water-soluble organic anion, it cannot easily penetrate the lipid bilayer of the cell membrane. As the precise mechanisms of the effect of pravastatin on glucose metabolism and di...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 1999
W Jacobsen G Kirchner K Hallensleben L Mancinelli M Deters I Hackbarth L Z Benet K F Sewing U Christians

In an in vitro study, the cytochrome P-450 3A (CYP3A)-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-Co A reductase inhibitors lovastatin and pravastatin were compared. Lovastatin was metabolized by human liver microsomes to two major metabolites: 6'beta-hydroxy [Michaelis-Menten constant (Km): 7.8 +/- 2.7 microM] and 6'-exomethylene lovastatin (Km,10.3 +/- 2.6 mic...

Journal: :The Journal of pharmacology and experimental therapeutics 2001
D Nakai R Nakagomi Y Furuta T Tokui T Abe T Ikeda K Nishimura

Involvement of LST-1 (a human liver-specific transporter, also called OATP2) as the major transporter in the uptake of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, by human liver was demonstrated. The hepatic uptake of pravastatin evaluated using human hepatocytes was Na(+)-independent and reached saturation with a Michaelis constant (K(m)) of 11.5 +/- 2.2 microM. T...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Valérie Haydont Céline Bourgier Marc Pocard Antoine Lusinchi Jocelyne Aigueperse Denis Mathé Jean Bourhis Marie-Catherine Vozenin-Brotons

PURPOSES Intestinal complications after radiotherapy are caused by transmural fibrosis and impair the quality of life of cancer survivors. Radiation fibrosis was considered permanent and irreversible, but recently, its dynamic nature was shown, providing new opportunities for the development of antifibrotic therapies. Among these new targets, we identified the Rho/ROCK pathway and thought to in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید